



BioLayer Corporation Limited

17 May 2007

BioLayer Completes 2 Diagnostics Projects and Signs Up 2 Others

Brisbane based BioLayer Corporation (ASX:BLS) today announced it has successfully completed two (2) research projects it started with large US and European diagnostic companies in January this year.

One of the completed projects is with Beckman Coulter in Fullerton, California, a major player in the USD 5.0 billion global *in vitro* diagnostics market.

“Now that the preliminary work is done we are discussing commercial terms with these companies” said David Beins, BioLayer’s Managing Director and CEO who recently attended the 2007 BIO International Convention in Boston.

While at BIO Mr. Beins took the opportunity to sign new research agreements with another two (2) of the world’s largest *in vitro* diagnostics companies in the US.

This brings to four (4) the total number of projects with multinational diagnostic companies undertaken at BioLayer since the beginning of the year, ensuring the company remains on track to fulfill its previously announced 3-Year business plan.

“I am pleased to see BioLayer’s technology being validated by major diagnostics companies like Beckman, as we knew it would” said Mr. Beins.

“The fact these companies are successively entering agreements with us shows the high demand BioLayer’s innovative surface coatings have generated on the global stage, both in the United States and Europe where we have focused our business development efforts” he said.

“Subject to current discussions I expect the projects we recently completed will lead to BioLayer’s technology being incorporated into cutting-edge immunoassay products sold worldwide by these companies to aid in the diagnosis of critical conditions such as heart disease, life-threatening infections like hepatitis, and cancer” he continued.

BioLayer Corporation is an Australian material sciences company specialising in the design and assembly of multi-component coatings for the solid phase of immunoassay and bioseparations. BioLayer’s proprietary coatings bind, orient and protect proteins such as antibodies in specific ways that enhance functionality. In the case of immunoassay this results in dramatically improved performance like better sensitivity, and cost savings like batch-to-batch reproducibility. In bioseparations it means a totally synthetic and robust surface that specifically and reversibly binds any target protein. BioLayer works with many types of solid phase materials and formats, like beads of different kinds, membranes and plates. For more information, visit www.bio-layer.com.

BioLayer Corporation Limited ABN 75 070 028 625
Unit 4, 26 Brandl Street, Eight Mile Plains QLD 4113
Phone 07 3219 0085 Fax 07 3219 0553 Email contact@biolayercorp.com
Web www.biolayercorp.com